CCR9-ADC

CCR9-ADC is an experimental antibody-drug conjugate (ADC) designed to target the C-C motif chemokine receptor 9 (CCR9) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL). The drug consists of a humanized anti-CCR9 monoclonal antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine, using site-specific click-chemistry. CCR9 is frequently expressed on T-lymphoblasts in relapsed and refractory T-ALL but has limited expression on normal tissues, providing a therapeutic window. Research indicates that CCR9 expression can be significantly upregulated by mTOR inhibitors (such as torin1) through an ARID1A-RUNX1 dependent mechanism, which enhances the cytotoxic efficacy of the ADC. In preclinical models, CCR9-ADC has demonstrated potent in vitro killing and significant in vivo anti-tumor activity.

Other names

anti-CCR9 ADCanti-CCR-9 ADCanti-CCR 9 ADCanti-CCR9-tesirine ADCanti-CCR-9-tesirine ADCanti-CCR 9-tesirine ADC